drugset / Trial / NCT05704634
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Phase 1
Active not recruiting
56 enrolled
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.
Timeline
- Start
- 2023-08-18
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Subcutaneous |
| Subject | Sarilumab | Monoclonal antibody | — | Intravenous |